arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Assertio Holdings, Inc.

ASRT
— Price unavailable
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
30 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Bearish
auto_awesome

Analytical Summary

Assertio Holdings, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth -62.5% ↘
Op. Margin -185.9% ↘
ROIC -16.1% ↘
FCF / Share $1.33
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity 0.52
info Valuation on last close.

30-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.93M
↓ -62.5% —
Net Income Profit after all expenses
$-18.86M
↓ -39.3% —
Operating Margin Operating profit as % of sales
-185.9%
↓ -114.3% 11th
FCF / Share Free cash flow per share
$1.33
↑ +279.2% —
Long-Term Debt Long-term obligations
$39.25M
— +0.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
9
Returns ↓
22
Financial Health ↓
44
Cash Quality
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 30 quarters